Skip to main content
. Author manuscript; available in PMC: 2010 Aug 10.
Published in final edited form as: Semin Hematol. 2008 Apr;45(2):90–94. doi: 10.1053/j.seminhematol.2008.02.003

Table 2.

Randomized Clinical Trials Comparing Rituximab Plus Chemotherapy to Chemotherapy Alone for Untreated Follicular Lymphoma

Study Group Regimen N Follow-up PFS
 OS
R-Chemo Chemo R-Chemo Chemo
GLSG10 CHOP 428 2 year 82% 64% 95% 90%
GELA-GOELAMS11 CHVP-IFN 358 3.5 year 67% 46% 91% 84%
International12 CVP 321 4 year 54% 17% 83% 77%
OSHO13 MCP 201 4 year 71% 40% 87% 74%

NOTE. All differences in PFS and OS are statistically significant at the .05 level.

Abbreviations: Chemo, chemotherapy; R, rituximab; GLSG, German Low Grade Lymphoma Study Group; GELA, Group d’Etude des Lymphomas de I’Adulte; GOELAMS, Groupe Ouest Est des Leucemies et Autres Maladies du Sang; OSHO, East German Study Group Hematology and oncology.